Plain-English translation of NCT07105059 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 study testing whether two medications— and —work well together to treat multiple myeloma that has come back or stopped responding to earlier treatments. The study will help researchers understand if this combination is safe and effective for patients like you who have already tried standard therapies.
Multiple myeloma can become resistant to standard treatments, leaving patients with few options. This medication combination uses a new approach that activates your immune system to fight the cancer cells, offering hope for those whose disease no longer responds to conventional therapy.
You likely qualify if…
You likely don't qualify if…
You will first receive alone for 14 days to prepare your cancer cells and activate your immune system. After that, you will gradually increase your dose of (the bispecific antibody) before receiving both medications together. Throughout the study, you will have regular clinic visits for blood tests, physical exams, and scans to monitor how well the treatment is working and how you are tolerating it.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States